Skip to main content
SpringerLink
Log in

Nebennierenrindenkarzinom

  • Chapter
  • First Online:
Uroonkologie

  • 2831 Accesses

Zusammenfassung

Das Nebennierenrindenkarzinom ist häufig ein sehr aggressiver Tumor, dessen Pathogenese weitgehend ungeklärt ist. Die Einteilung dieser seltenen uroonkologischen Krebserkrankung beruht auf der TNM-Klassifikation. Dieses Kapitel beschreibt neben Risikofaktoren das diagnostische Vorgehen – Hormondiagnostik, Ausbreitungs- und Target-spezifische Diagnostik, Bildgebung. Das therapeutische Vorgehen differenziert zwischen der Therapie des lokal begrenzten und des fortgeschrittenen Nebennierenrindenkarzinoms. Die Prognose dieses urologischen Malignoms ist ebenso dargelegt wie Empfehlungen zur Nachsorge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Abraham J, Bakke S, Rutt A et al. (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94: 2333–2343

    Article  PubMed  CAS  Google Scholar 

  • Allolio B, Hahner S, Weismann D et al. (2004) Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60: 273–287

    Google Scholar 

  • Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM (2011) Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 96 (12): 3775–3784

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M and Baudin E (2007). Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92 (1): 148–54

    Article  PubMed  CAS  Google Scholar 

  • Baudin E, Pellegriti G, Bonnay M et al. (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92: 1385–1392

    Article  PubMed  CAS  Google Scholar 

  • Becherer A, Vierhapper H, Potzi C et al. (2001) FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 16: 289–295

    Article  PubMed  CAS  Google Scholar 

  • Berruti A, Terzolo M, Pia A et al. (1998) Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83: 2194–2200

    Article  PubMed  CAS  Google Scholar 

  • Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M; German Adrenocortical Carcinoma Registry Group. (2010) Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58 (4): 609–615

    Article  Google Scholar 

  • Caoili EM, Korobkin M, Francis IR et al. (2000) Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol 175: 1411–1415

    Article  PubMed  CAS  Google Scholar 

  • Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B (/2009) Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol 160 (6): 1003–1010

    Google Scholar 

  • Fassnacht M, Hahner S, Banfelder N et al. (2005) Diagnostik und Therapie des Nebennierenrinden-Karzinoms. DÄ 102: 1670–1675

    Google Scholar 

  • Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M and Allolio B (2006). Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91 (11): 4501–4

    Article  PubMed  CAS  Google Scholar 

  • Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B (2010) Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 95 (11): 4925–32

    Article  PubMed  CAS  Google Scholar 

  • Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115 (2): 243–250

    Article  PubMed  Google Scholar 

  • Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B (2012) Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med 2012 [Epub ahead of print]

    Google Scholar 

  • Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, Beuschlein F, Zink M, Lang K, Allolio B and Schirbel A (2008). [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab 93 (6): 2358–65

    Article  PubMed  CAS  Google Scholar 

  • Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65 (4): 765–773

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E (2011) Plasma concentrations of o, p’DDD, o, p’DDA, and o, p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96 (6): 1844–51

    Article  PubMed  CAS  Google Scholar 

  • Jain M, Rechache N, Kebebew E (2012) Molecular markers of adrenocortical tumors. J Surg Oncol [Epub ahead of print]

    Google Scholar 

  • Khan TS, Imam H, Juhlin C et al. (2000) Streptozocin and o, p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11: 1281–1287

    Article  PubMed  CAS  Google Scholar 

  • Lau SK, Weiss LM (2009) The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Human Pathol 40: 757–768

    Article  Google Scholar 

  • Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E (2010) Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 162 (6): 1147–1153

    Article  PubMed  CAS  Google Scholar 

  • Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI (2010) The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 46 (4): 713–719

    Article  PubMed  Google Scholar 

  • Pena CS, Boland GW, Hahn PF et al. (2000) Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217: 798–802

    Article  PubMed  CAS  Google Scholar 

  • Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritte C, Strasburger C, Allolio B and Fassnacht M (2008). Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93 (6): 2057–62

    Article  PubMed  CAS  Google Scholar 

  • Saeger W (2000) Histopathological classification of adrenal tumours. Eur J Clin Invest 30 Suppl 3: 58–62

    Article  PubMed  Google Scholar 

  • Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M and Worden FP (2005). Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12 (3): 667–680

    Article  PubMed  CAS  Google Scholar 

  • Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 17 (2): 445–453

    Article  PubMed  CAS  Google Scholar 

  • Terzolo M, Ali A, Osella G et al. (2000) The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. Eur J Endocrinol 142: 611–617

    Article  PubMed  CAS  Google Scholar 

  • Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L and Berruti A (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356 (23): 2372–80

    Article  PubMed  CAS  Google Scholar 

  • Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ 3rd (2010) Adrenocortical carcinoma: the influence of large vessel extension. Surgery 148 (6): 1057–1064

    Article  PubMed  Google Scholar 

  • Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13: 202–206

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ENDOC Zentrum für Endokrine Tumoren und Praxis für Endokrinologie, Andrologie und medikamentöse Tumor therapie, Altonaerstraße 59, D-20357, Hamburg, Deutschland

    S. Petersenn

  2. WINEG Bramfelder, Straße 140, D-22305, Hamburg, Deutschland

    K. Mann

  3. Klinik für Nuklearmedizin Universit ätsklinikum Essen, Hufelandstraße 55, D-45122, Essen, Germany

    I. Nagarajah & A. Bockisch

  4. Klinik und Poliklinik für Urologie Universitätsklinikum Essen, Hufelandstraße 55, D-45122, Essen, Germany

    H. Rübben

Authors
  1. S. Petersenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Nagarajah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Bockisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Urologie, Universitätsklinikum Essen, Essen, Germany

    Herbert Rübben

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Petersenn, S., Mann, K., Nagarajah, I., Bockisch, A., Rübben, H. (2014). Nebennierenrindenkarzinom. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35032-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35032-0_18

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35031-3

  • Online ISBN: 978-3-642-35032-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation